Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
HIV/AIDS drug development and treatment
TopicLeading institutions, researchers & key papers
This cluster of papers focuses on the efficacy and safety of antiretroviral therapy for HIV infection, including the development of drug resistance, the use of integrase inhibitors and reverse transcriptase inhibitors, and the adverse effects such as hepatotoxicity and renal toxicity. It also explores the use of nucleoside analogues for treating viral diseases.
274
Works
IDs:OpenAlex
How has HIV/AIDS drug development and treatment's publication output changed over time?
ScholarIQpublication output · 2000–2018
Output declined50% over the shown period — from 2 works in 2000 to 1 in 2018.
2
2
1
1
1
1
1
1
1
1
2000200120022003200520082010201120162018
What are the most-cited papers on HIV/AIDS drug development and treatment?
ScholarIQmost cited works
Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine
Ann C. Collier, Robert W. Coombs, David Schoenfeld, Roland L. Bassett, Joseph Timpone, Alice Baruch, Michelle Jones, Karen Facey, Caroline C. Whitacre, Vincent McAuliffe, Harvey M. Friedman, Thomas C. Merigan, Richard C. Reichman, Carol J. Hooper, Lawrence Corey
New England Journal of Medicine. 1996758 CitationsOPEN ACCESS
Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development
Sanjay R. Chemburkar, John F. Bauer, Kris C. Deming, Harry Spiwek, Ketan Patel, John B. Morris, Rodger F. Henry, Stephen G. Spanton, Walter Dziki, W.W. Porter, J. Quick, Phil J. Bauer, John Donaubauer, B. A. Narayanan, Mauro Soldani, Dave Riley, Kathyrn McFarland
S107255770. 2000684 Citations
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Kenneth A. Freedberg, Elena Losina, Milton C. Weinstein, A. David Paltiel, Calvin Cohen, George R. Seage, Donald E. Craven, Hong Zhang, April D. Kimmel, Sue J. Goldie
New England Journal of Medicine. 2001520 CitationsOPEN ACCESS
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
John D. Baxter, Douglas L. Mayers, Deborah Wentworth, James D. Neaton, Marie L. Hoover, Mark A. Winters, Sharon Mannheimer, Melanie Thompson, Donald I. Abrams, Barbara Brizz, John P. A. Ioannidis, Thomas C. Merigan
S20605092. 2000502 Citations
Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors
Frederick Hecht, Robert M. Grant, Christos J. Petropoulos, Beth Dillon, Margaret A. Chesney, Huan Tian, Nicholas S. Hellmann, Nirmala I. Bandrapalli, Laura Digilio, Bernard M. Branson, James O. Kahn
New England Journal of Medicine. 1998453 CitationsOPEN ACCESS
Where is HIV/AIDS drug development and treatment research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on HIV/AIDS drug development and treatment is open access?
ScholarIQopen access share
67%OPEN ACCESS
Gold
0%
Green
27%
Hybrid
0%
Bronze
40%
Closed
33%
Related on ScholarIQ
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Paper
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
Paper
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Paper
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials
Paper
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus 1 with Zidovudine Treatment
Paper
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Paper